Table 1.
Examples of New Vaccines and New Vaccine Formulations Approved for Human Use in the Past 20 Years (1993–2013)
| Vaccine Antigen | Year | Protection Against | Vaccine Product
|
Vaccine Formulation
|
|||
|---|---|---|---|---|---|---|---|
| Name | Manufacturer | Dosage | Adjuvant | Admin Route | |||
| Polysaccharide-protein conjugates | 1993 | Haemophilus influenzae type b | ActHIB | Sanofi Pasteur | Lyo | None | IM |
| 2000/2010 | Pneumococcal | Prevnar/Prevnar 13 | Pfizer | Liquid | Aluminum | IM | |
| 2005/2010 | Meningococcal | Menactra/Menveo | Sanofi Pasteur/Novartis | Liquid/Lyo | None | IM | |
| Live, attenuated virus | 1995 | Varicella (Chicken Pox) | Varivax | Merck | Lyo | None | SC |
| 2005 | Measles, mumps, rubella and chickenpox | ProQuad | Merck | Lyo | None | SC | |
| 2006 | Varicella (Shingles) | Zostavax | Merck | Lyo | None | SC | |
| 2006/2008 | Rotavirus | Rotateq/Rotarix | Merck/GSK | Liquid/Lyo | None | Oral | |
| Inactivated virus | 1995/1996 | Hepatitis A | Havrix/Vaqta | GSK/Merck | Liquid | Aluminum | IM |
| 2009 | Japanese encephalitis | IXIARO | Novartis | Liquid | Aluminum | IM | |
| Recombinant protein virus-like-particle | 2006/2009 | Human papillomavirus (HPV) | Gardasil/Cervarix | Merck/GSK | Liquid | Aluminum/AS04 | IM |
| New flu vaccines | |||||||
| (live vaccine) | 2003 | Influenza | FluMist | Medimmune | Liquid | None | Nasal |
| (intradermal delivery) | 2011 | Fluzone Intradermal |
Sanofi Pasteur | Liquid | None | ID | |
| (cell culture) | 2012 | Fluarix | Novartis | Liquid | None | IM | |
| (recombinant protein) | 2013 | Flublok | Protein Science | Liquid | None | IM | |
| (biodefense stockpile only) | 2013 | Influenza A (H5N1) | Influenza A (H5N1) virus monovalent vaccine, adjuvanted | GSK | Liquid | AS03 | IM |
This table is not a comprehensive list of approved vaccines by regulatory agencies, but rather provides illustrative examples from US FDA approvals of vaccine development trends in terms of types of new vaccine antigens, formulations, and delivery routes (7).